1,265
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

, , , , , , , , & show all
Pages 34-43 | Accepted 21 Aug 2015, Published online: 30 Sep 2015

References

  • Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010;62:1576-82
  • Meier FM, Frerix M, Hermann W, et al. Current immunotherapy in rheumatoid arthritis. Immunotherapy 2013;5:955-74
  • Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med 2014;47:37-45
  • Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009;8:546-59
  • Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(2 Suppl):ii14-17
  • Day MS, Nam D, Goodman S, et al. Psoriatic arthritis. J Am Acad Orthop Surg 2012;20:28-37
  • Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012;51:571-6
  • Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650-7
  • Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
  • Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014;48–49:128-33
  • ORENCIA® (abatacept) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2015
  • Humira® (adalimumab) Prescribing Information. North Chicago, IL: AbbVie Inc., 2014
  • CIMZIA® (certolizumab pegol) Prescribing Information. Smyrna, GA: UCB, Inc., 2013
  • Enbrel® (etanercept) Prescribing Information. Thousand Oaks, CA: lmmunex Corporation, 2015
  • SIMPONI® (golimumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., 2014
  • Remicade® (infliximab) Prescribing Information. Malvern, PA: Janssen Biotech, Inc., 2015
  • RITUXAN® (rituximab) Prescribing Information. South San Francisco, CA: Genentech, Inc., 2014
  • ACTEMRA® (tocilizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc., 2014
  • STELARA® (ustekinumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., 2014
  • Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88
  • Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29:234-48
  • Bonafede M, Joseph GJ, Princic N, et al. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ 2013;16:1120-8
  • Howe A, Eyck LT, Dufour R, et al. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm 2014;20:1236-44
  • Joyce AT, Gandra SR, Fox KM, et al. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naive rheumatoid arthritis patients in US health plans. J Med Econ 2014;17:1-10
  • Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15:264-75
  • Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19:621-30
  • Wu N, Lee YC, Shah N, et al. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin Ther 2014;36:1231-41, 41 e1–3
  • Bonafede M, Joseph GJ, Shah N, et al. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoecon Outcomes Res 2014;6:381-8
  • Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the Veterans Health Administration. Health Aff (Millwood) 2014;33:1203-11
  • Nelson SD, Lu CC, Teng CC, et al. The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf 2015;24:86-92
  • Lu CC, Leng J, Cannon G, et al. Accuracy of a natural language processing software designed to compute average weekly dose from narrative medication schedule [abstract]. Value Health 2014;17:A187-8
  • Cannon GW, Mikuls TR, Hayden CL, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011;63:1680-90
  • Cannon GW, DuVall SL, Haroldsen CL, et al. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol 2014;41:1935-43
  • Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.